HomeInsightsStock Comparison

Dr Reddys Laboratories Ltd vs Lupin Ltd Stock Comparison

Dr Reddys Laboratories Ltd vs Lupin Ltd Stock Comparison

Last Updated on: May 02, 2025

Key Highlights

  • The Latest Trading Price of Dr Reddys Laboratories Ltd is ₹ 1183 as of 30 Apr 15:30.
  • The P/E Ratio of Dr Reddys Laboratories Ltd changed from 25.6 on March 2020 to 18.4 on March 2024 . This represents a CAGR of -6.39% over 5 yearsThe P/E Ratio of Lupin Ltd changed from 38.1 on March 2021 to 38.5 on March 2024 . This represents a CAGR of 0.26% over 4 years.
  • The Market Cap of Dr Reddys Laboratories Ltd changed from ₹ 51797 crore on March 2020 to ₹ 102679 crore on March 2024 . This represents a CAGR of 14.67% over 5 yearsThe Market Cap of Lupin Ltd changed from ₹ 26713 crore on March 2020 to ₹ 73722 crore on March 2024 . This represents a CAGR of 22.51% over 5 years.
  • The revenue of Dr Reddys Laboratories Ltd for the Dec '24 is ₹ 8535 crore as compare to the Sep '24 revenue of ₹ 8351 crore. This represent the growth of 2.2% The revenue of Lupin Ltd for the Dec '24 is ₹ 5821 crore as compare to the Sep '24 revenue of ₹ 5715 crore. This represent the growth of 1.86%.
  • The ebitda of Dr Reddys Laboratories Ltd for the Dec '24 is ₹ 2427 crore as compare to the Sep '24 ebitda of ₹ 2390 crore. This represent the growth of 1.56% The ebitda of Lupin Ltd for the Dec '24 is ₹ 1409 crore as compare to the Sep '24 ebitda of ₹ 1382 crore. This represent the growth of 1.95%.
  • The net profit of Dr Reddys Laboratories Ltd changed from ₹ 1405 crore to ₹ 1404 crore over 7 quarters. This represents a CAGR of -0.03% The net profit of Lupin Ltd changed from ₹ 453.33 crore to ₹ 858.86 crore over 7 quarters. This represents a CAGR of 44.07% .
  • The Dividend Payout of Dr Reddys Laboratories Ltd changed from 14.14 % on March 2020 to 15.37 % on March 2024 . This represents a CAGR of 1.68% over 5 yearsThe Dividend Payout of Lupin Ltd changed from 37.36 % on March 2020 to 15.67 % on March 2024 . This represents a CAGR of -15.95% over 5 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Dr Reddys Laboratories Ltd

  • Dr Reddy's Laboratories Limited (DRL) is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives.
  • Through its three businesses - Pharmaceutical Services &Active Ingredients, Global Generics and Proprietary Products - Dr. Reddy's offers a portfolio of products and services including Active Pharmaceutical Ingredients (APIs), custom pharmaceutical services, generics, biosimilars and differentiated formulations.
  • The company's major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology.
  • Dr. Reddy's operates in markets across the globe.
  • Its major markets include - USA, India, Russia & CIS countries, and Europe. Dr Reddy's Laboratories Limited was incorporated in 1984 in Hyderabad.

About Lupin Ltd

  • Lupin is an innovation led Transnational Pharmaceutical Company producing, developing and marketing a wide range of branded & generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.
  • The Company has significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, Central Nervous System (CNS), Gastro-Intestinal (GI), Anti-Infective and Nonsteroidal Anti Inflammatory Drug (NSAID) therapy segments and is a global leader in the Anti-TB and Cephalosporins segments. Lupin Limited was incorporated in the year 1983 with the name Lupin Chemicals Limited.
  • In March 2001, Lupin Laboratories Limited was amalgamated with the company and the name was changed to Lupin Limited.
  • In the year 1987, the company commenced operations in Cephalexin Plant at Mandideep and 7 ADCA plant at Ankleshwar.

Dr Reddys Laboratories Ltd News Hub

News

Dr Reddys announces cessation of subsidiary in Louisiana

Dr. Reddy's Laboratories Inc., USA, a wholly owned subsidiary of the Company, has successf...

Read more

24 Mar 2025 13:48

News

Dr Reddys Laboratories to conduct board meeting

Dr Reddys Laboratories will hold a meeting of the Board of Directors of the Company on 9 M...

Read more

22 Mar 2025 11:01

News

Dr. Reddy's recalls Levetiracetam in 0.75% Sodium Chloride Injection 1,000 mg/100 mL in US

Dr. Reddy's Laboratories is recalling one Batch/Lot No: A1540076 of Levetiracetam in 0.75%...

Read more

13 Mar 2025 18:46

News

Dr Reddys Laboratories allots 11,250 equity shares under ESOS

Dr Reddys Laboratories has allotted 11,250 equity shares under ESOS on 06 March 2025. Powe...

Read more

06 Mar 2025 19:16

News

Dr Reddy's Lab gets EIR from USFDA for Hyderabad facility

The USFDA has classified the inspection as Voluntary Action Indicated (VAI) and confirmed ...

Read more

27 Feb 2025 09:57

News

Dr Reddys Laboratories allots 20,155 equity shares under ESOS

Dr Reddys Laboratories has allotted 20,155 equity shares of Re.1/- each of the Company, fu...

Read more

14 Feb 2025 18:24

Lupin Ltd News Hub

News

Lupin announces board meeting date

Lupin will hold a meeting of the Board of Directors of the Company on 14 May 2025. Powered...

Read more

30 Apr 2025 11:10

News

Lupin receives USFDA approval for Tolvaptan Tablets

 Lupin has received approval from the United States Food and Drug Administration (U.S. FDA...

Read more

24 Apr 2025 11:06

News

Lupin rallies after receiving USFDA nod for Tolvaptan tablets

The drug is bioequivalent to Jynarque' Tablets by Otsuka Pharmaceutical Company. Lupin is ...

Read more

24 Apr 2025 11:40

News

Lupin gets EIR from USFDA for Nagpur facility

The EIR was issued following an inspection of the facility conducted from 10 June to 13 Ju...

Read more

17 Apr 2025 15:00

News

Lupin allots 24,101 equity shares under ESOP

Lupin has allotted 24,101 equity shares under ESOP on 21 March 2025. In view of the above,...

Read more

21 Mar 2025 16:10

News

Nanomi wins prestigious CMO Award for Life Science Leadership in Drug Delivery

Nanomi B.V., a Dutch subsidiary of the global pharma major Lupin, today announced that it ...

Read more

21 Mar 2025 19:12

SWOT Analysis Of Lupin Ltd

Strength

3

S

Weakness

2

W

Opportunity

0

O

Threats

1

T

SWOT Analysis Of Dr Reddys Laboratories Ltd

Strength

2

S

Weakness

2

W

Opportunity

0

O

Threats

1

T

BlinkX Score for Lupin Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Dr Reddys Laboratories Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Dr Reddys Laboratories Ltd and Lupin Ltd

Which company has a larger market capitalization, Dr Reddys Laboratories Ltd or Lupin Ltd?

Market cap of Dr Reddys Laboratories Ltd is 98,716 Cr while Market cap of Lupin Ltd is 95,634 Cr

What are the key factors driving the stock performance of Dr Reddys Laboratories Ltd and Lupin Ltd?

The stock performance of Dr Reddys Laboratories Ltd and Lupin Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Dr Reddys Laboratories Ltd and Lupin Ltd?

As of May 2, 2025, the Dr Reddys Laboratories Ltd stock price is INR ₹1183.0. On the other hand, Lupin Ltd stock price is INR ₹2094.65.

How do dividend payouts of Dr Reddys Laboratories Ltd and Lupin Ltd compare?

To compare the dividend payouts of Dr Reddys Laboratories Ltd and Lupin Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions